Nicola Horlick
Chair
Nicola read Law at Balliol College, Oxford and was made an Honorary Fellow of Balliol in 2019. She has over thirty-five years of experience managing funds and was responsible for leading the development of some of the UK’s best known fund management companies, including Mercury Asset Management (now BlackRock), Morgan Grenfell Asset Management (now Aberdeen) and SG Asset Management, where she built assets under management to £7 billion within three years.
In 2004, Nicola set up Bramdean Asset Management LLP with Sir Derek Higgs and the business was launched at the beginning of 2005. Bramdean ran a number of alternative investment mandates before selling the bulk of its business to Aberdeen at the end of 2009. In 2011, Nicola became one of the founding partners and Chair of Rockpool Investments LLP, a private equity business. She remained as Chair until early 2015.
In 2013, Nicola co-founded Money&Co. and remains as its CEO today. Money&Co. allows individuals and family offices looking for a better return on cash to lend to good quality SMEs based in the UK.
Nicola became Chair of the Board of Trustees of Anthony Nolan in July 2021. She is also Chair of the Nominations Committee, and a member of the Audit and Finance, and Governance and Risk, Committees.
Martin Laws
Vice-Chair
Following an initial career in international construction and commercial property, Martin spent 25 years in business consultancy roles including, from 2002 to 2018, as a partner at Deloitte. A Chartered Civil Engineer and Fellow of the RICS, Martin also has an MBA in International Business from City University Business School, London.
In his consultancy career, Martin advised a diverse range of companies, charities and Government bodies, both in the UK and internationally, latterly with a particular focus on the implications of fast-moving technology and changing workforce expectations on their future operations and workplaces. Martin now works as an executive coach and as an independent advisor to a number of start-up and fast-growing companies.
Martin became a Trustee of Anthony Nolan in March 2018 and was appointed as Vice Chair of the Board of Trustees on 24 July 2023. He is also the Chair of the Governance and Risk Committee and a member of the Audit & Finance Committee and the Nominations Committee.
Dr Susan Conroy
Susan Conroy completed a PhD and post-doctoral research in molecular biology at University College London, before moving to work in a variety of scientific and commercial roles within the pharmaceutical and biotechnology industry. She specialised in the identification, evaluation, management and commercialisation of pharmaceutical and biotechnology projects and also worked as a consultant covering technology transfer, medical affairs and commercial exploitation of existing products.
Susan became Chief Executive of Therakind Ltd in 2007, a company she helped to set up to increase the availability of authorised speciality medicines and ensure that these medicines are both safe and effective. As Chief Executive, Susan leads the company’s strategy, identifying and negotiating key agreements and commercial opportunities as well as leading the day-to-day operations of the company. Under her leadership, Therakind has successfully completed eight clinical trials and gained regulatory approval for three medicines.
Susan became a Trustee of Anthony Nolan in January 2022 and is a member of the Governance and Risk Committee and a member of the Audit and Finance Committee.
Debbie Lee
As the Executive Director, Finance for Grosvenor Property UK, Debbie brings expertise of financial management and governance. She has over 25 years’ experience of providing financial, commercial and strategic advice at the Board level. Prior to joining Grosvenor in 2014, Debbie was a Director in Deloitte’s Real Estate Corporate Finance team having qualified as a Chartered Accountant at PwC.
In her spare time Debbie enjoys Pilates, playing netball and spending time with her family.
Debbie became a Trustee of Anthony Nolan in November 2022 and was appointed as Chair of the Audit and Finance Committee on 24 July 2023. She also brings her personal experience of going through blood cancer.
Robert Leeming
Robert Leeming is an experienced investor with a diverse background spanning private equity, academia, charity and public service.
Robert read Natural Sciences at Trinity College, Cambridge before moving into the private sector, where he spent 23 years in private equity, first as a Partner at Charterhouse Capital and currently as a Partner at Foundation Investments. During this time, he has sat on 20 boards across a range of sectors and invested over 2 billion of capital, supporting companies through periods of growth, transformation, and strategic change.
Alongside his professional career, Robert pursued his passion for understanding human behaviour with an MsC at the London School of Economics. He also holds an MBA from INSEAD Business School.
Robert previously founded and chaired the Autism Research Trust, a charity dedicated to supporting research into autism. He has also served as a Non-Executive Director for the government Department for Business and Trade, bringing his commercial expertise and scientific insight to public policy and governance.
He has personal understanding of blood cancer through his brother’s experience and is committed to applying his skills and experience to help Anthony Nolan further its mission to save lives.
Robert became a Trustee of Anthony Nolan in June 2025.
Philomena McManus
Phil has worked in the field of communications for over 30 years. She is a proven leader in developing impactful communication strategies across diverse platforms. Phil has extensive experience in crisis management and a wealth of experience in external and internal comms. Her experience spans consultancy and global businesses such as Vodafone, Sky, Rolls- Royce and Worldpay.
She has provided strategic advice to board level leadership teams and led global projects involving multinational audiences. Phil is currently an external advisor to businesses in Corporate Affairs and Private Equity.
Phil studied Strategy at London Business School and Leadership at the IMD in Lausanne, Switzerland. She also studied the History of Politics at Oxford as an online course during Covid.
Outside of business, Phil enjoys Pilates, reading, travel and spending time with friends and her family in Scotland.
Phil became a Trustee of Anthony Nolan in June 2025.
Matt Miller
Matt is Creative Director at Born Social, a global social media agency bringing social-first thinking to the brands of tomorrow. He previously founded Oddigy, a culture-aware creative studio building commercial brands and campaigns.
Matt’s expertise and leadership in creative, branding and visual messaging has crossed all sectors. From global charities and NGOs to luxury brands, celebrities and music artists, his ability to build diverse and experienced teams and solutions has been pivotal in providing access for the next generation of talent and generating meaningful impact.
Matt has personal experience of blood disorders as his family has been impacted by them, and by virtue of the fact that he himself is a carrier of the sickle cell blood disorder trait. He is excited by the opportunity that joining the Board of Trustees provides for his own narrative to contribute to saving lives and inspiring life-saving action within communities.
Matt became a Trustee of Anthony Nolan in January 2022 and is a member of the Audit and Finance Committee.
Katy Minshall
Katy Minshall is Director of Public Policy at PlayStation. In this role, she covers a wide range of public policy and technology issues. Prior to PlayStation, Katy worked at Twitter as UK Director of Public Policy, where she focused on online safety and government regulation. Alongside this, her role also involved working with charities in the UK, as well as coordinating with government departments on issues ranging from public safety to the Covid-19 pandemic.
Prior to working in the technology sector, Katy was a civil servant in the Cabinet Office, and previously worked as a parliamentary researcher. She holds a masters degree in public policy from Harvard University’s Kennedy School of Government.
Katy lives in London with her wife Emily and their daughter. She has personal experience of cancer, having been successfully treated for a synovial sarcoma in 2021.
Katy became a trustee of Anthony Nolan in April 2023.
Dr Victoria Potter
Dr Victoria Potter is a Haematologist specialising in myeloid malignancy and stem cell transplantation at King’s College Hospital, London, UK. She completed early postgraduate and specialty training in Sydney, Australia followed by a clinical fellowship at King’s College Hospital.
In 2017 she was appointed Transplant Programme Director at Kings College Hospital. She has specialist interests in AML, prevention of relapse post-transplant and development of transplantation strategies for sickle cell disease. She is research active and committed to development of clinical trials in myeloid malignancies and transplantation. She is a member of the AML NCRI working party steering group and Chair of the relapse sub-group of this committee.
Victoria is secretary of the BSBMTCT clinical trials sub-committee, a member of the BSBMTCT Executive and an IMPACT (UK prospective clinical trials network) deputy medical director. Victoria became a Trustee of Anthony Nolan in July 2023 and is a member of the Nominations Committee.
Sreeram Ramagopalan
Sreeram (Ram) Ramagopalan completed a PhD in Epidemiology at the University of Oxford before pursuing an MSc in Health Economics and an MBA from the London School of Economics and Political Science. With over 330 journal publications, Ram is an internationally recognised expert in health economics and the analysis of medical data. Ram is currently a Senior Lecturer at the Centre for Pharmaceutical Medicine Research, King's College London, and works as a consultant to life science companies helping them to get their medicines reimbursed and ultimately for patients to access them- a focus that has defined his career over the last 15 years.
Ram has personal experience of friends being impacted with blood cancer and family members diagnosed with cancer.
Ram became a Trustee of Anthony Nolan in June 2025.
Mark Ritson
Mark is a control engineer who has worked all over the world designing and commissioning complex control systems for offshore oil, steel making plants and other large-scale industrial projects. He is now the Managing Director of Inspec Solutions, a company he founded in 2000. Inspec Solutions provide large scale control and software systems to the industrial and commercial sectors.
Mark was diagnosed with Severe Aplastic Anaemia in early 2008, with no bone marrow match worldwide he was forced to follow alternative therapies until 2012 when his disease returned and a transplant was the only option. Fortunately, weeks earlier a young German woman had registered and was a match. In 2013 Mark had two transplants, the second being successful and he is now back to almost normal health. In 2016 he ran the London Marathon to raise funds for Anthony Nolan and in 2018 ran a half marathon with his donor, Jacqueline in Germany.
Mark also previously sat on the board of the NHSE Clinical Reference Group for Bone Marrow Transplantation for three years, working collaboratively with clinical experts helping develop national service standards, quality standards, commissioning policies and plans for NHS England.
He is a keen reader, runner and tennis player and a very keen fly fisherman.
Mark became a Trustee of Anthony Nolan in 2019 and is a member of the Governance and Risk Committee. He brings his personal experience of going through blood cancer and blood disorders having had a bone marrow transplant himself. He also has a deep understanding of technology, data, and business from his professional career as well as experience of the NHS at a national commissioning level.